Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric J Devor

Showing results (51-60 of 70) with videos related to

Pageof 7
Sort By:
Pharmaceuticals (Basel, Switzerland)|August 6, 2021
Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with ChemotherapyJianling Bi, Garima Dixit, Yuping Zhang, et al.
International Journal of Molecular Sciences|March 15, 2019
Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian CancerMegan E McDonald, Erin A Salinas, Eric J Devor, et al.
Scientific Reports|March 17, 2021
Creation and validation of models to predict response to primary treatment in serous ovarian cancerJesus Gonzalez Bosquet, Eric J Devor, Andreea M Newtson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 5, 2017
Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor HistologyEric J Devor, Henry D Reyes, Jesus Gonzalez-Bosquet, et al.
Physiological Reports|January 21, 2015
Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit preeclampsia phenotypesMark K Santillan, Christopher J Pelham, Pimonrat Ketsawatsomkron, et al.
Gynecologic Oncology|November 3, 2015
Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devicesHenry D Reyes, Matthew J Carlson, Eric J Devor, et al.
Translational Oncology|September 7, 2025
Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53Lane E Smith, Jamie L Padilla, Angelina Licor, et al.
Cancer Management and Research|June 27, 2019
An integrated prediction model of recurrence in endometrial endometrioid cancersMarina D Miller, Erin A Salinas, Andreea M Newtson, et al.
International Journal of Molecular Sciences|March 13, 2019
A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular VariablesErin A Salinas, Marina D Miller, Andreea M Newtson, et al.
Oncotarget|September 18, 2014
Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancerShujie Yang, Yichen Jia, Xiaoyue Liu, et al.
Pageof 7

Showing results (51-60 of 70) with videos related to

Sort By:
Pageof 7
Pharmaceuticals (Basel, Switzerland)|August 6, 2021
Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with ChemotherapyJianling Bi, Garima Dixit, Yuping Zhang, et al.
International Journal of Molecular Sciences|March 15, 2019
Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian CancerMegan E McDonald, Erin A Salinas, Eric J Devor, et al.
Scientific Reports|March 17, 2021
Creation and validation of models to predict response to primary treatment in serous ovarian cancerJesus Gonzalez Bosquet, Eric J Devor, Andreea M Newtson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 5, 2017
Placenta-Specific Protein 1 Expression in Human Papillomavirus 16/18-Positive Cervical Cancers Is Associated With Tumor HistologyEric J Devor, Henry D Reyes, Jesus Gonzalez-Bosquet, et al.
Physiological Reports|January 21, 2015
Pregnant mice lacking indoleamine 2,3-dioxygenase exhibit preeclampsia phenotypesMark K Santillan, Christopher J Pelham, Pimonrat Ketsawatsomkron, et al.
Gynecologic Oncology|November 3, 2015
Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devicesHenry D Reyes, Matthew J Carlson, Eric J Devor, et al.
Translational Oncology|September 7, 2025
Novel p53 reactivators that are synergistic with olaparib for the treatment of gynecologic cancers with mutant p53Lane E Smith, Jamie L Padilla, Angelina Licor, et al.
Cancer Management and Research|June 27, 2019
An integrated prediction model of recurrence in endometrial endometrioid cancersMarina D Miller, Erin A Salinas, Andreea M Newtson, et al.
International Journal of Molecular Sciences|March 13, 2019
A Prediction Model for Preoperative Risk Assessment in Endometrial Cancer Utilizing Clinical and Molecular VariablesErin A Salinas, Marina D Miller, Andreea M Newtson, et al.
Oncotarget|September 18, 2014
Systematic dissection of the mechanisms underlying progesterone receptor downregulation in endometrial cancerShujie Yang, Yichen Jia, Xiaoyue Liu, et al.
Pageof 7